Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2015 August;150(4) > Giornale Italiano di Dermatologia e Venereologia 2015 August;150(4):467-71

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Per citare questo articolo

 

CASE REPORTS   

Giornale Italiano di Dermatologia e Venereologia 2015 August;150(4):467-71

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

Use of infliximab in toxic epidermal necrolysis: a still opened challenge

Ganzetti G. 1, Campanati A. 1, Simonetti O. 1, Giuliodori K. 1, Giangiacomi M. 2, Lemme G. 2, Offidani A. 1

1 Dermatological Clinic, Department of Clinical and Molecular Medicine, Polytechnic Marche University, Ancona, Italy; 2 Anatomic Pathology Institute, Department of Neurosciences, Polytechnic University Of Marche, Ancona, Italy


PDF


Toxic epidermal necrolysis (TEN), also known as Lyell syndrome, is a potential life-threatening muco-cutaneous disease with important systemic implications. It affects the skin and mucous membranes, with involvement of more than 30% of body surface and it is mostly caused by drugs. Although the pathogenesis is not fully elucidated, it is probably linked to the inability to detoxicate reactive metabolites of drugs, to genetic susceptibility and to immune factors leading to cellular apoptosis. Currently, there are no randomized control trials and stardardized therapeutical approaches for the management of Lyell syndrome; therefore controversial clinical responses to the most common used drug in TEN make it difficult for the clinical-therapeutic approach. The authors reported their experience on three patients affected by Lyell syndrome treated with infliximab.

inizio pagina